xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT06012448</url>
    </required_header>
    <id_info>
      <org_study_id>HUM00227361</org_study_id>
      <nct_id>NCT06012448</nct_id>
    </id_info>
    <brief_title>The Immunologic Effects of Dupilumab in the Treatment of Dermal Hypersensitivity Reaction</brief_title>
    <official_title>The Immunologic Effects of Dupilumab in the Treatment of Dermal Hypersensitivity Reaction</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>University of Michigan</agency>
        <agency_class>Other</agency_class>
      </lead_sponsor>
      <collaborator>
        <agency>Regeneron Pharmaceuticals</agency>
        <agency_class>Industry</agency_class>
      </collaborator>
    </sponsors>
    <source>University of Michigan</source>
    <oversight_info>
      <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
      <is_us_export>No</is_us_export>
    </oversight_info>
    <brief_summary>
      <textblock>
        This research is studying a drug called dupilumab to learn about its safety and its effect as&#xD;
        a treatment for participants with dermal hypersensitivity reaction. This study will help&#xD;
        better understand why and how dermal hypersensitivity reaction occurs and how dupilumab might&#xD;
        help treat this condition.&#xD;
      </textblock>
    </brief_summary>
    <detailed_description>
      <textblock>
        Dermal hypersensitivity reaction is a skin rash that can happen as a reaction to a known&#xD;
        trigger or it can happen for unknown reasons. Not a lot is known about why the rash occurs&#xD;
        and what happens to the immune system to cause this rash. Dupilumab, a biologic drug that is&#xD;
        given as an injection under the skin, may treat dermal hypersensitivity reaction. This study&#xD;
        tries to better understand dermal hypersensitivity reaction and how the immune system&#xD;
        responds to dupilumab.&#xD;
      </textblock>
    </detailed_description>
    <overall_status>Not yet recruiting</overall_status>
    <start_date type="Anticipated">September 2023</start_date>
    <completion_date type="Anticipated">December 2024</completion_date>
    <primary_completion_date type="Anticipated">October 2024</primary_completion_date>
    <phase>Phase 4</phase>
    <study_type>Interventional</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <allocation>N/A</allocation>
      <intervention_model>Single Group Assignment</intervention_model>
      <primary_purpose>Treatment</primary_purpose>
      <masking>None (Open Label)</masking>
    </study_design_info>
    <primary_outcome>
      <measure>Change in Th2 immune cell population in lesional Dermal hypersensitivity reaction (DHR) skin at week 16 compared to week 0.</measure>
      <time_frame>Week 0, week 16</time_frame>
    </primary_outcome>
    <secondary_outcome>
      <measure>Changes in Total Body surface area (TBSA) in patients with DHR treated with dupilumab at week 2 from week 0.</measure>
      <time_frame>Week 0, week 2</time_frame>
      <description>The TBSA involvement of DHR will be assessed by the investigator or trained designee for each part of the body (the possible highest score for each region is head and neck [9%], anterior trunk [18%], back [18%], upper limbs [18%], lower limbs [36%], and genitals [1%]) and will be reported as a percentage of all major body sections combined.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Changes in Total Body surface area in patients with DHR treated with dupilumab at week 8 from week 0.</measure>
      <time_frame>Week 0, week 8</time_frame>
      <description>The TBSA involvement of DHR will be assessed by the investigator or trained designee for each part of the body (the possible highest score for each region is head and neck [9%], anterior trunk [18%], back [18%], upper limbs [18%], lower limbs [36%], and genitals [1%]) and will be reported as a percentage of all major body sections combined.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Changes in Total Body surface area in patients with DHR treated with dupilumab at week 16 from week 0.</measure>
      <time_frame>Week 0, week 16</time_frame>
      <description>The TBSA involvement of DHR will be assessed by the investigator or trained designee for each part of the body (the possible highest score for each region is head and neck [9%], anterior trunk [18%], back [18%], upper limbs [18%], lower limbs [36%], and genitals [1%]) and will be reported as a percentage of all major body sections combined.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Changes in Total Body surface area in patients with DHR treated with dupilumab at week 24 from week 0.</measure>
      <time_frame>Week 0, week 24</time_frame>
      <description>The TBSA involvement of DHR will be assessed by the investigator or trained designee for each part of the body (the possible highest score for each region is head and neck [9%], anterior trunk [18%], back [18%], upper limbs [18%], lower limbs [36%], and genitals [1%]) and will be reported as a percentage of all major body sections combined.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Changes in Investigator Global Assessment (IGA) in patients with DHR treated with dupilumab at week 2 from week 0.</measure>
      <time_frame>Week 0, 2 weeks</time_frame>
      <description>The IGA is a 5-point scale ranging from 0 (clear) to 4 (severe) used by the investigator or trained designee to evaluate the global severity of Dermal Hypersensitivity Reaction and the clinical response to a treatment. Treatment success is defined as 0 (clear) or 1 (almost clear) and a 2-point improvement from baseline.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Changes in Investigator Global Assessment in patients with DHR treated with dupilumab at week 8 from week 0.</measure>
      <time_frame>Week 0, 8 weeks</time_frame>
      <description>The IGA is a 5-point scale ranging from 0 (clear) to 4 (severe) used by the investigator or trained designee to evaluate the global severity of Dermal Hypersensitivity Reaction and the clinical response to a treatment. Treatment success is defined as 0 (clear) or 1 (almost clear) and a 2-point improvement from baseline.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Changes in Investigator Global Assessment in patients with DHR treated with dupilumab at week 16 from week 0.</measure>
      <time_frame>Week 0, 16 weeks</time_frame>
      <description>The IGA is a 5-point scale ranging from 0 (clear) to 4 (severe) used by the investigator or trained designee to evaluate the global severity of Dermal Hypersensitivity Reaction and the clinical response to a treatment. Treatment success is defined as 0 (clear) or 1 (almost clear) and a 2-point improvement from baseline.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Changes in Investigator Global Assessment in patients with DHR treated with dupilumab at week 24 from week 0.</measure>
      <time_frame>Week 0, 24weeks</time_frame>
      <description>The IGA is a 5-point scale ranging from 0 (clear) to 4 (severe) used by the investigator or trained designee to evaluate the global severity of Dermal Hypersensitivity Reaction and the clinical response to a treatment. Treatment success is defined as 0 (clear) or 1 (almost clear) and a 2-point improvement from baseline.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Changes in Pruritus Numeric Rating Scale (NRS) for average itch intensity at week 2 from week 0.</measure>
      <time_frame>Week 0, 2 weeks</time_frame>
      <description>This scale is used to report the intensity of pruritus during the last 24 hours. The Average Pruritus NRS (AP NRS) provides a measure of overall pruritus intensity over a given period and has clinical relevance to both subjects and physicians because peak pruritus may show higher intensity but short duration. Participants will select from a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Changes in Pruritus Numeric Rating Scale (NRS) for average itch intensity at week 8 from week 0.</measure>
      <time_frame>Week 0, 8 weeks</time_frame>
      <description>This scale is used to report the intensity of pruritus during the last 24 hours. The Average Pruritus NRS (AP NRS) provides a measure of overall pruritus intensity over a given period and has clinical relevance to both subjects and physicians because peak pruritus may show higher intensity but short duration. Participants will select from a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Changes in Pruritus Numeric Rating Scale (NRS) for average itch intensity at week 16 from week 0.</measure>
      <time_frame>Week 0, 16 weeks</time_frame>
      <description>This scale is used to report the intensity of pruritus during the last 24 hours. The Average Pruritus NRS (AP NRS) provides a measure of overall pruritus intensity over a given period and has clinical relevance to both subjects and physicians because peak pruritus may show higher intensity but short duration. Participants will select from a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Changes in Pruritus Numeric Rating Scale (NRS) for average itch intensity at week 24 from week 0.</measure>
      <time_frame>Week 0, 24 weeks</time_frame>
      <description>This scale is used to report the intensity of pruritus during the last 24 hours. The Average Pruritus NRS (AP NRS) provides a measure of overall pruritus intensity over a given period and has clinical relevance to both subjects and physicians because peak pruritus may show higher intensity but short duration. Participants will select from a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Changes in Pruritus Numeric Rating Scale (NRS) for maximum itch intensity 2 from week 0.</measure>
      <time_frame>Week 0, 2 weeks</time_frame>
      <description>This scale is used to report the intensity of pruritus during the last 24 hours. The maximum itch intensity will be noted by the participants by indicating on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Changes in Pruritus Numeric Rating Scale (NRS) for maximum itch intensity 8 from week 0.</measure>
      <time_frame>Week 0, 8 weeks</time_frame>
      <description>This scale is used to report the intensity of pruritus during the last 24 hours. The maximum itch intensity will be noted by the participants by indicating on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Changes in Pruritus Numeric Rating Scale (NRS) for maximum itch intensity 16 from week 0.</measure>
      <time_frame>Week 0, 16 weeks</time_frame>
      <description>This scale is used to report the intensity of pruritus during the last 24 hours. The maximum itch intensity will be noted by the participants by indicating on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Changes in Pruritus Numeric Rating Scale (NRS) for maximum itch intensity 24 from week 0.</measure>
      <time_frame>Week 0, 24 weeks</time_frame>
      <description>This scale is used to report the intensity of pruritus during the last 24 hours. The maximum itch intensity will be noted by the participants by indicating on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'.</description>
    </secondary_outcome>
    <number_of_arms>1</number_of_arms>
    <enrollment type="Anticipated">10</enrollment>
    <condition>Dermal Hypersensitivity Reaction</condition>
    <arm_group>
      <arm_group_label>Dupilumab</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>All patients will receive dupilumab.</description>
    </arm_group>
    <intervention>
      <intervention_type>Drug</intervention_type>
      <intervention_name>Dupilumab</intervention_name>
      <description>Patients will start by getting dupilumab 600 milligram (mg) subcutaneously at week 0, followed by 300 mg every 2 weeks starting at week 2. The last dose will be given at week 24.&#xD;
  In addition, participants will have visits at the research site for examinations, provide health information, laboratory draws, skin biopsies (at certain time points). Participation in the study will last approximately 28 weeks.</description>
      <arm_group_label>Dupilumab</arm_group_label>
      <other_name>Dupixent</other_name>
    </intervention>
    <eligibility>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
            -  Established diagnosis of chronic idiopathic DHR as defined by presence of clinical and&#xD;
               histopathologic features of DHR for at least 6 weeks without an underlying cause or&#xD;
               associated trigger&#xD;
  &#xD;
            -  Moderate-to-severe DHR as defined by greater or equal 5% total body-surface-area&#xD;
               (TBSA) involvement and IGA of greater or equal to 3.&#xD;
  &#xD;
            -  Female subjects of childbearing potential (i.e., fertile, following menarche and until&#xD;
               becoming post-menopausal unless permanently sterile) must agree either to commit to&#xD;
               true abstinence throughout the study and for 12 weeks after the last study drug&#xD;
               injection, when this is in line with the preferred and usual lifestyle of the subject,&#xD;
               or to use an adequate and approved method of contraception throughout the study and&#xD;
               for 12 weeks after the last study drug injection.&#xD;
  &#xD;
            -  Subject willing and able to comply with all of the time commitments and procedural&#xD;
               requirements of the clinical study protocol.&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
            -  Subjects meeting 1 or more of the following criteria at screening or baseline:&#xD;
  &#xD;
            -  Had an exacerbation of asthma requiring hospitalization in the preceding 12 months.&#xD;
  &#xD;
            -  Reporting asthma that has not been well-controlled (ie, symptoms occurring on &gt;2 days&#xD;
               per week, nighttime awakenings 2 or more times per week, or some interference with&#xD;
               normal activities) during the preceding 3 months.&#xD;
  &#xD;
            -  Subjects with a current medical history of chronic obstructive pulmonary disease&#xD;
               and/or chronic bronchitis.&#xD;
  &#xD;
            -  Cutaneous infection within 1 week before the baseline visit, any infection requiring&#xD;
               treatment with oral or parenteral antibiotics, antivirals, antiparasitics, or&#xD;
               antifungals within 2 weeks before the baseline visit.&#xD;
  &#xD;
            -  Confirmed or suspected COVID-19 infection within 4 weeks before the screening or&#xD;
               baseline visit.&#xD;
  &#xD;
            -  Previous treatment with dupilumab.&#xD;
  &#xD;
            -  Pregnant women (positive urine pregnancy test result at the screening visit or the&#xD;
               baseline visit), breastfeeding women, or women planning a pregnancy during the&#xD;
               clinical study.&#xD;
  &#xD;
            -  History of, current, or suspected lymphoproliferative disease or malignancy of any&#xD;
               organ system within the last 5 years, except for basal cell carcinoma, squamous cell&#xD;
               carcinoma in situ (Bowen's disease), or carcinomas in situ of the cervix that have&#xD;
               been treated and have no evidence of recurrence in the last 12 weeks before the&#xD;
               baseline visit.&#xD;
  &#xD;
            -  History of hypersensitivity (including anaphylaxis) to an immunoglobulin product&#xD;
               (plasma-derived or recombinant, i.e., monoclonal antibody) or to lidocaine.&#xD;
  &#xD;
            -  Known active or latent tuberculosis (TB) infection.&#xD;
  &#xD;
            -  Known or suspected immunosuppression or unusually frequent, recurrent, severe, or&#xD;
               prolonged infections as per investigator judgment.&#xD;
  &#xD;
            -  History of or current confounding skin condition (i.e., active atopic dermatitis,&#xD;
               chronic urticaria, psoriasis, cutaneous T-cell lymphoma [mycosis fungoides or Sezary&#xD;
               syndrome], contact dermatitis, chronic actinic dermatitis, dermatitis herpetiformis).&#xD;
  &#xD;
            -  Planned or expected major surgical procedure during the clinical study.&#xD;
  &#xD;
            -  Currently participating or participated in any other study of a drug or device, within&#xD;
               the past 8 weeks before the screening visit, or is in an exclusion period (if&#xD;
               verifiable) from a previous study.&#xD;
  &#xD;
            -  History of alcohol or substance abuse within 6 months of the screening.&#xD;
  &#xD;
            -  History of poor wound healing or keloid formation.&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>18 Years</minimum_age>
      <maximum_age>N/A</maximum_age>
      <healthy_volunteers>No</healthy_volunteers>
    </eligibility>
    <overall_official>
      <last_name>Mio Nakamura, MD, MS</last_name>
      <role>Principal Investigator</role>
      <affiliation>University of Michigan</affiliation>
    </overall_official>
    <overall_contact>
      <last_name>Nicole Nechiporchik</last_name>
      <phone>734-936-7519</phone>
      <email>nnechipo@umich.edu</email>
    </overall_contact>
    <location>
      <facility>
        <name>University of Michigan</name>
        <address>
          <city>Ann Arbor</city>
          <state>Michigan</state>
          <zip>48109</zip>
          <country>United States</country>
        </address>
      </facility>
      <contact>
        <last_name>Nicole Nechiporchik</last_name>
        <phone>734-936-7519</phone>
        <email>nnechipo@umich.edu</email>
      </contact>
      <investigator>
        <last_name>Mio Nakamura, MD, MS</last_name>
        <role>Principal Investigator</role>
      </investigator>
      <investigator>
        <last_name>Johann Gudjonsson, MD, PhD</last_name>
        <role>Sub-Investigator</role>
      </investigator>
      <investigator>
        <last_name>Allison Billi, MD, PhD</last_name>
        <role>Sub-Investigator</role>
      </investigator>
    </location>
    <location_countries>
      <country>United States</country>
    </location_countries>
    <verification_date>August 2023</verification_date>
    <study_first_submitted>August 21, 2023</study_first_submitted>
    <study_first_submitted_qc>August 21, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">August 25, 2023</study_first_posted>
    <last_update_submitted>August 21, 2023</last_update_submitted>
    <last_update_submitted_qc>August 21, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">August 25, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Principal Investigator</responsible_party_type>
      <investigator_affiliation>University of Michigan</investigator_affiliation>
      <investigator_full_name>Mio Nakamura</investigator_full_name>
      <investigator_title>Assistant Professor of Dermatology</investigator_title>
    </responsible_party>
    <keyword>Skin rash</keyword>
    <keyword>Dupilumab</keyword>
    <keyword>Skin biopsies</keyword>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Hypersensitivity</mesh_term>
    </condition_browse>
    <patient_data>
      <sharing_ipd>No</sharing_ipd>
    </patient_data>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT06012448
  org study id: HUM00227361
  nct id: NCT06012448
  lead sponsor: 
  collaborator: 
  is fda regulated drug: Yes
  is fda regulated device: No
  is us export: No
  This research is studying a drug called dupilumab to learn about its safety and its effect as
        a treatment for participants with dermal hypersensitivity reaction. This study will help
        better understand why and how dermal hypersensitivity reaction occurs and how dupilumab might
        help treat this condition.
  Dermal hypersensitivity reaction is a skin rash that can happen as a reaction to a known
        trigger or it can happen for unknown reasons. Not a lot is known about why the rash occurs
        and what happens to the immune system to cause this rash. Dupilumab, a biologic drug that is
        given as an injection under the skin, may treat dermal hypersensitivity reaction. This study
        tries to better understand dermal hypersensitivity reaction and how the immune system
        responds to dupilumab.
  allocation: N/A
  intervention model: Single Group Assignment
  primary purpose: Treatment
  masking: None (Open Label)
  measure: Change in Th2 immune cell population in lesional Dermal hypersensitivity reaction (DHR) skin at week 16 compared to week 0.
  time frame: Week 0, week 16
  measure: Changes in Total Body surface area (TBSA) in patients with DHR treated with dupilumab at week 2 from week 0.
  time frame: Week 0, week 2
  description: The TBSA involvement of DHR will be assessed by the investigator or trained designee for each part of the body (the possible highest score for each region is head and neck [9%], anterior trunk [18%], back [18%], upper limbs [18%], lower limbs [36%], and genitals [1%]) and will be reported as a percentage of all major body sections combined.
  measure: Changes in Total Body surface area in patients with DHR treated with dupilumab at week 8 from week 0.
  time frame: Week 0, week 8
  description: The TBSA involvement of DHR will be assessed by the investigator or trained designee for each part of the body (the possible highest score for each region is head and neck [9%], anterior trunk [18%], back [18%], upper limbs [18%], lower limbs [36%], and genitals [1%]) and will be reported as a percentage of all major body sections combined.
  measure: Changes in Total Body surface area in patients with DHR treated with dupilumab at week 16 from week 0.
  time frame: Week 0, week 16
  description: The TBSA involvement of DHR will be assessed by the investigator or trained designee for each part of the body (the possible highest score for each region is head and neck [9%], anterior trunk [18%], back [18%], upper limbs [18%], lower limbs [36%], and genitals [1%]) and will be reported as a percentage of all major body sections combined.
  measure: Changes in Total Body surface area in patients with DHR treated with dupilumab at week 24 from week 0.
  time frame: Week 0, week 24
  description: The TBSA involvement of DHR will be assessed by the investigator or trained designee for each part of the body (the possible highest score for each region is head and neck [9%], anterior trunk [18%], back [18%], upper limbs [18%], lower limbs [36%], and genitals [1%]) and will be reported as a percentage of all major body sections combined.
  measure: Changes in Investigator Global Assessment (IGA) in patients with DHR treated with dupilumab at week 2 from week 0.
  time frame: Week 0, 2 weeks
  description: The IGA is a 5-point scale ranging from 0 (clear) to 4 (severe) used by the investigator or trained designee to evaluate the global severity of Dermal Hypersensitivity Reaction and the clinical response to a treatment. Treatment success is defined as 0 (clear) or 1 (almost clear) and a 2-point improvement from baseline.
  measure: Changes in Investigator Global Assessment in patients with DHR treated with dupilumab at week 8 from week 0.
  time frame: Week 0, 8 weeks
  description: The IGA is a 5-point scale ranging from 0 (clear) to 4 (severe) used by the investigator or trained designee to evaluate the global severity of Dermal Hypersensitivity Reaction and the clinical response to a treatment. Treatment success is defined as 0 (clear) or 1 (almost clear) and a 2-point improvement from baseline.
  measure: Changes in Investigator Global Assessment in patients with DHR treated with dupilumab at week 16 from week 0.
  time frame: Week 0, 16 weeks
  description: The IGA is a 5-point scale ranging from 0 (clear) to 4 (severe) used by the investigator or trained designee to evaluate the global severity of Dermal Hypersensitivity Reaction and the clinical response to a treatment. Treatment success is defined as 0 (clear) or 1 (almost clear) and a 2-point improvement from baseline.
  measure: Changes in Investigator Global Assessment in patients with DHR treated with dupilumab at week 24 from week 0.
  time frame: Week 0, 24weeks
  description: The IGA is a 5-point scale ranging from 0 (clear) to 4 (severe) used by the investigator or trained designee to evaluate the global severity of Dermal Hypersensitivity Reaction and the clinical response to a treatment. Treatment success is defined as 0 (clear) or 1 (almost clear) and a 2-point improvement from baseline.
  measure: Changes in Pruritus Numeric Rating Scale (NRS) for average itch intensity at week 2 from week 0.
  time frame: Week 0, 2 weeks
  description: This scale is used to report the intensity of pruritus during the last 24 hours. The Average Pruritus NRS (AP NRS) provides a measure of overall pruritus intensity over a given period and has clinical relevance to both subjects and physicians because peak pruritus may show higher intensity but short duration. Participants will select from a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'.
  measure: Changes in Pruritus Numeric Rating Scale (NRS) for average itch intensity at week 8 from week 0.
  time frame: Week 0, 8 weeks
  description: This scale is used to report the intensity of pruritus during the last 24 hours. The Average Pruritus NRS (AP NRS) provides a measure of overall pruritus intensity over a given period and has clinical relevance to both subjects and physicians because peak pruritus may show higher intensity but short duration. Participants will select from a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'.
  measure: Changes in Pruritus Numeric Rating Scale (NRS) for average itch intensity at week 16 from week 0.
  time frame: Week 0, 16 weeks
  description: This scale is used to report the intensity of pruritus during the last 24 hours. The Average Pruritus NRS (AP NRS) provides a measure of overall pruritus intensity over a given period and has clinical relevance to both subjects and physicians because peak pruritus may show higher intensity but short duration. Participants will select from a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'.
  measure: Changes in Pruritus Numeric Rating Scale (NRS) for average itch intensity at week 24 from week 0.
  time frame: Week 0, 24 weeks
  description: This scale is used to report the intensity of pruritus during the last 24 hours. The Average Pruritus NRS (AP NRS) provides a measure of overall pruritus intensity over a given period and has clinical relevance to both subjects and physicians because peak pruritus may show higher intensity but short duration. Participants will select from a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'.
  measure: Changes in Pruritus Numeric Rating Scale (NRS) for maximum itch intensity 2 from week 0.
  time frame: Week 0, 2 weeks
  description: This scale is used to report the intensity of pruritus during the last 24 hours. The maximum itch intensity will be noted by the participants by indicating on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'.
  measure: Changes in Pruritus Numeric Rating Scale (NRS) for maximum itch intensity 8 from week 0.
  time frame: Week 0, 8 weeks
  description: This scale is used to report the intensity of pruritus during the last 24 hours. The maximum itch intensity will be noted by the participants by indicating on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'.
  measure: Changes in Pruritus Numeric Rating Scale (NRS) for maximum itch intensity 16 from week 0.
  time frame: Week 0, 16 weeks
  description: This scale is used to report the intensity of pruritus during the last 24 hours. The maximum itch intensity will be noted by the participants by indicating on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'.
  measure: Changes in Pruritus Numeric Rating Scale (NRS) for maximum itch intensity 24 from week 0.
  time frame: Week 0, 24 weeks
  description: This scale is used to report the intensity of pruritus during the last 24 hours. The maximum itch intensity will be noted by the participants by indicating on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'.
  arm group label: Dupilumab
  arm group type: Experimental
  description: All patients will receive dupilumab.
  intervention type: Drug
  intervention name: Dupilumab
  description: Patients will start by getting dupilumab 600 milligram (mg) subcutaneously at week 0, followed by 300 mg every 2 weeks starting at week 2. The last dose will be given at week 24.
  In addition, participants will have visits at the research site for examinations, provide health information, laboratory draws, skin biopsies (at certain time points). Participation in the study will last approximately 28 weeks.
  arm group label: Dupilumab
  other name: Dupixent
  criteria: 
  gender: All
  minimum age: 18 Years
  maximum age: N/A
  healthy volunteers: No
  last name: Mio Nakamura, MD, MS
  role: Principal Investigator
  affiliation: University of Michigan
  last name: Nicole Nechiporchik
  phone: 734-936-7519
  email: nnechipo@umich.edu
  facility: 
  contact: 
  investigator: 
  investigator: 
  investigator: 
  country: United States
  responsible party type: Principal Investigator
  investigator affiliation: University of Michigan
  investigator full name: Mio Nakamura
  investigator title: Assistant Professor of Dermatology
  mesh term: Hypersensitivity
  sharing ipd: No